Performance analysis of Neumora Therapeutics (NMRA)
Annual Return
Since Sep 14, 2023, NMRA has had an average annual return of -56.08%, underperforming the benchmark SPY, which returned +20.73% annual.
| 2026 | 2025 | 2024 | 2023 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.93% | -83.11% | -37.83% | +0.29% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +11.21% | +75.32% | -44.13% | +26.68% | -25.12% | -8.09% | -4.10% | -8.93% | |||||
| 2025 | -81.80% | -19.12% | -35.95% | -21.94% | -8.28% | +2.38% | +167.52% | -11.71% | +5.21% | +65.83% | -25.79% | -20.11% | -83.11% |
| 2024 | -12.60% | +18.32% | -22.01% | -33.89% | +8.92% | -0.72% | +30.84% | -10.58% | +14.87% | -13.33% | -13.18% | +6.64% | -37.83% |
| 2023 | -17.00% | -22.60% | +12.17% | +39.18% | +0.29% |
Drawdown analysis of Neumora Therapeutics (NMRA)
The maximum drawdown for the NMRA was -96.89%, occurring on May 14, 2025. This drawdown has not yet recovered.
The current NMRA drawdown is -91.75%.
Since Sep 14, 2023 NMRA has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 3 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.89% | Feb 16, 2024 | 310 | May 14, 2025 | Ongoing | Ongoing | Ongoing |
| -43.29% | Sep 14, 2023 | 20 | Oct 12, 2023 | 50 | Dec 22, 2023 | 70 |
| -21.50% | Dec 27, 2023 | 12 | Jan 16, 2024 | 18 | Feb 9, 2024 | 30 |
| -3.79% | Feb 9, 2024 | 2 | Feb 13, 2024 | 2 | Feb 15, 2024 | 4 |